Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

How can the integrity of occupational and environmental health research be maintained in the presence of conflicting interests?

Baur X, Soskolne CL, Bero LA.

Environ Health. 2019 Nov 4;18(1):93. doi: 10.1186/s12940-019-0527-x.

2.

Response to Acquavella J, conflict of interest: a hazard for epidemiology.

Soskolne CL, Advani S, Sass J, Bero LA, Ruff K.

Ann Epidemiol. 2019 Aug;36:62-63. doi: 10.1016/j.annepidem.2019.07.010. Epub 2019 Jul 16. No abstract available.

PMID:
31401133
3.

Conflicts of interest between the sugary food and beverage industry and dental research organisations: time for reform.

Kearns CE, Bero LA.

Lancet. 2019 Jul 20;394(10194):194-196. doi: 10.1016/S0140-6736(19)31277-2. No abstract available.

PMID:
31327353
4.

Making nutrition guidelines fit for purpose.

Bero LA, Norris SL, Lawrence MA.

BMJ. 2019 Apr 16;365:l1579. doi: 10.1136/bmj.l1579. No abstract available.

PMID:
30992263
5.

A review of methods used for hazard identification and risk assessment of environmental hazards.

Chartres N, Bero LA, Norris SL.

Environ Int. 2019 Feb;123:231-239. doi: 10.1016/j.envint.2018.11.060. Epub 2018 Dec 8. Review.

6.

Philip Morris International-funded 'Foundation for a Smoke-Free World': analysing its claims of independence.

van der Eijk Y, Bero LA, Malone RE.

Tob Control. 2019 Nov;28(6):712-718. doi: 10.1136/tobaccocontrol-2018-054278. Epub 2018 Sep 21.

PMID:
30242044
7.

Food industry sponsorship of academic research: investigating commercial bias in the research agenda.

Fabbri A, Holland TJ, Bero LA.

Public Health Nutr. 2018 Dec;21(18):3422-3430. doi: 10.1017/S1368980018002100. Epub 2018 Aug 30.

PMID:
30157979
8.

Not All Influences on Science Are Conflicts of Interest.

Bero LA, Grundy Q.

Am J Public Health. 2018 May;108(5):632-633. doi: 10.2105/AJPH.2018.304334. No abstract available.

PMID:
29617619
9.

Improving the Use of Research Evidence in Guideline Development [Internet].

Oxman AD, Schünemann HJ, Fretheim A, Boyd EA, Bero LA, Tan-Torres Edejer T.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Mar.

10.

Study sponsorship and the nutrition research agenda: analysis of cohort studies examining the association between nutrition and obesity.

Fabbri A, Chartres N, Bero LA.

Public Health Nutr. 2017 Dec;20(17):3193-3199. doi: 10.1017/S1368980017002178. Epub 2017 Aug 30.

PMID:
28851466
11.

A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia.

Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, Bero LA.

BMJ Open. 2017 Jun 30;7(6):e016701. doi: 10.1136/bmjopen-2017-016701.

12.

Tracing the Potential Flow of Consumer Data: A Network Analysis of Prominent Health and Fitness Apps.

Grundy Q, Held FP, Bero LA.

J Med Internet Res. 2017 Jun 28;19(6):e233. doi: 10.2196/jmir.7347.

13.

Interpretation and use of evidence in state policymaking: a qualitative analysis.

Apollonio DE, Bero LA.

BMJ Open. 2017 Feb 20;7(2):e012738. doi: 10.1136/bmjopen-2016-012738.

14.

Why Having a (Nonfinancial) Interest Is Not a Conflict of Interest.

Bero LA, Grundy Q.

PLoS Biol. 2016 Dec 21;14(12):e2001221. doi: 10.1371/journal.pbio.2001221. eCollection 2016 Dec.

15.

Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity.

Fabbri A, Chartres N, Scrinis G, Bero LA.

Public Health Nutr. 2017 May;20(7):1306-1313. doi: 10.1017/S1368980016003128. Epub 2016 Dec 19. Review.

PMID:
27989264
16.

Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis.

Chartres N, Fabbri A, Bero LA.

JAMA Intern Med. 2016 Dec 1;176(12):1769-1777. doi: 10.1001/jamainternmed.2016.6721. Review.

PMID:
27802480
17.
18.

Challenges in Assessing Mobile Health App Quality: A Systematic Review of Prevalent and Innovative Methods.

Grundy QH, Wang Z, Bero LA.

Am J Prev Med. 2016 Dec;51(6):1051-1059. doi: 10.1016/j.amepre.2016.07.009. Epub 2016 Sep 19. Review.

PMID:
27659122
20.

Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States.

Apollonio DE, Wolfe N, Bero LA.

BMC Public Health. 2016 Aug 18;16(1):822. doi: 10.1186/s12889-016-3461-7. Review.

21.

A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals.

Vandenberg LN, Ågerstrand M, Beronius A, Beausoleil C, Bergman Å, Bero LA, Bornehag CG, Boyer CS, Cooper GS, Cotgreave I, Gee D, Grandjean P, Guyton KZ, Hass U, Heindel JJ, Jobling S, Kidd KA, Kortenkamp A, Macleod MR, Martin OV, Norinder U, Scheringer M, Thayer KA, Toppari J, Whaley P, Woodruff TJ, Rudén C.

Environ Health. 2016 Jul 14;15(1):74. doi: 10.1186/s12940-016-0156-6. Review.

22.

Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry.

Grundy Q, Bero LA, Malone RE.

Ann Intern Med. 2016 Jun 7;164(11):733-9. doi: 10.7326/M15-2522. Epub 2016 Apr 5.

23.
24.
26.

Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles.

Forsyth SR, Odierna DH, Krauth D, Bero LA.

Syst Rev. 2014 Nov 18;3:122. doi: 10.1186/2046-4053-3-122. Review.

27.

Term limits and the tobacco industry.

Apollonio DE, Glantz SA, Bero LA.

Soc Sci Med. 2014 Mar;104:1-5. doi: 10.1016/j.socscimed.2013.11.005. Epub 2013 Nov 15.

28.

Why the Cochrane risk of bias tool should include funding source as a standard item.

Bero LA.

Cochrane Database Syst Rev. 2013 Dec 20;(12):ED000075. doi: 10.1002/14651858.ED000075. No abstract available.

PMID:
24575439
29.

Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance.

Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV.

JAMA Intern Med. 2013 Dec 9-23;173(22):2032-6. doi: 10.1001/jamainternmed.2013.10559.

PMID:
23925593
30.

The cycle of bias in health research: a framework and toolbox for critical appraisal training.

Odierna DH, Forsyth SR, White J, Bero LA.

Account Res. 2013;20(2):127-41. doi: 10.1080/08989621.2013.768931.

31.

Critical appraisal training increases understanding and confidence and enhances the use of evidence in diverse categories of learners.

Odierna DH, White J, Forsyth S, Bero LA.

Health Expect. 2015 Apr;18(2):273-87. doi: 10.1111/hex.12030. Epub 2012 Dec 16.

32.

The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines.

Bero LA, Hill S, Habicht J, Mathiesen M, Starkopf J.

J Clin Epidemiol. 2013 Feb;66(2):132-9. doi: 10.1016/j.jclinepi.2012.07.007. Epub 2012 Sep 10. Review.

PMID:
22974497
33.

The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics.

Bero LA, Binder L.

J Clin Epidemiol. 2013 May;66(5):472-3. doi: 10.1016/j.jclinepi.2012.03.015. Epub 2012 Sep 5. No abstract available.

PMID:
22959591
34.

Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study.

Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD.

BMJ. 2012 Aug 16;345:e5155. doi: 10.1136/bmj.e5155.

35.

Tobacco industry denormalisation as a tobacco control intervention: a review.

Malone RE, Grundy Q, Bero LA.

Tob Control. 2012 Mar;21(2):162-70. doi: 10.1136/tobaccocontrol-2011-050200. Review.

36.

Conrad and Becker's "10 Criteria" fall short of addressing conflicts of interest in chemical safety studies.

Sutton P, Woodruff TJ, Vogel S, Bero LA.

Environ Health Perspect. 2011 Dec;119(12):A506-7; author reply A508-9. doi: 10.1289/ehp.1104385. No abstract available.

37.

Making systematic reviews global.

Bero LA, Ghersi D.

Cochrane Database Syst Rev. 2011 Feb 16;(8):ED000020. doi: 10.1002/14651858.ED000020. No abstract available.

PMID:
21833979
38.

Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement.

Walleser S, Hill SR, Bero LA.

J Clin Epidemiol. 2011 Dec;64(12):1331-40. doi: 10.1016/j.jclinepi.2011.04.006. Epub 2011 Jul 20. Review.

PMID:
21775103
39.

Applying the essential medicines concept to US preferred drug lists.

Millar TP, Wong S, Odierna DH, Bero LA.

Am J Public Health. 2011 Aug;101(8):1444-8. doi: 10.2105/AJPH.2010.300054. Epub 2011 Jun 16.

40.

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.

Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD.

JAMA. 2011 Mar 9;305(10):1008-17. doi: 10.1001/jama.2011.257. Review.

PMID:
21386079
41.

Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.

Dhruva SS, Bero LA, Redberg RF.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):165-71. doi: 10.1161/CIRCOUTCOMES.110.958215. Epub 2011 Mar 1. Review.

PMID:
21364127
42.

Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia.

Ridge AL, Bero LA, Hill SR.

BMC Health Serv Res. 2010 Dec 16;10:340. doi: 10.1186/1472-6963-10-340.

43.

Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies.

Chen CE, Dhruva SS, Bero LA, Redberg RF.

Arch Intern Med. 2011 Mar 28;171(6):534-9. doi: 10.1001/archinternmed.2010.445. Epub 2010 Nov 22.

PMID:
21098342
44.

"A delicate diplomatic situation": tobacco industry efforts to gain control of the Framingham Study.

Cataldo JK, Bero LA, Malone RE.

J Clin Epidemiol. 2010 Aug;63(8):841-53. doi: 10.1016/j.jclinepi.2010.01.021.

45.

Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.

Dhruva SS, Bero LA, Redberg RF.

JAMA. 2009 Dec 23;302(24):2679-85. doi: 10.1001/jama.2009.1899. Review. Erratum in: JAMA. 2010 Feb 3;303(5):422.

PMID:
20040556
46.

Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.

Cook DM, Gurugubelli RK, Bero LA.

Drug Saf. 2009;32(11):1057-66. doi: 10.2165/11316670-000000000-00000.

PMID:
19810777
47.

The politics of smoking in federal buildings: an executive order case study.

Cook DM, Bero LA.

Am J Public Health. 2009 Sep;99(9):1588-95. doi: 10.2105/AJPH.2008.151829. Epub 2009 Jul 16.

48.

Evidence and argument in policymaking: development of workplace smoking legislation.

Apollonio DE, Bero LA.

BMC Public Health. 2009 Jun 17;9:189. doi: 10.1186/1471-2458-9-189.

49.

Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations.

Odierna DH, Bero LA.

J Clin Epidemiol. 2009 Dec;62(12):1268-78. doi: 10.1016/j.jclinepi.2009.01.009. Epub 2009 Apr 17. Review.

PMID:
19375890
50.

Moral disengagement in the corporate world.

White J, Bandura A, Bero LA.

Account Res. 2009 Jan-Mar;16(1):41-74. doi: 10.1080/08989620802689847.

PMID:
19247852

Supplemental Content

Loading ...
Support Center